Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer
Research output: Contribution to journal › Journal article › Research › peer-review
Standard anti-proliferative chemotherapy is relatively ineffective against slowly proliferating androgen-independent prostate cancer cells within metastatic sites. In contrast, the lipophilic cytotoxin thapsigargin, which causes apoptosis by disrupting intracellular free Ca2+ levels, is effective against both proliferative and quiescent (i.e., G0-arrested) cells. However, thapsigargin's mechanism of action indicates that it is unlikely to be selective for cancer cells or prostate cells.
Original language | English |
---|---|
Journal | National Cancer Institute. Journal (Online) |
Volume | 95 |
Issue number | 13 |
Pages (from-to) | 990-1000 |
Number of pages | 11 |
ISSN | 1460-2105 |
Publication status | Published - 2 Jul 2003 |
- Animals, Antineoplastic Agents, Disease Models, Animal, Humans, Hydrolysis, Male, Mice, Mice, Nude, Prodrugs, Prostate-Specific Antigen, Prostatic Neoplasms, Thapsigargin, Transplantation, Heterologous, Treatment Outcome
Research areas
ID: 44569411